Systematic review of adverse event costs and cost-effectiveness analyses of anticancer drugs

Accurately quantifying adverse event (AE) cost is essential for cost-effectiveness analysis (CEAs) of anticancerr drugs. Misestimates in AE costs may significantly affect cost-effectiveness conclusions. A systematic review of 11 claims-based studies of AE costs and 102 CEAs, found that the proportion of AE costs among total medical costs was 10% higher and absolute costs $ 17,201 higher in claims-based studies than in CEAs, both statistically significant. Replacing AE costs in CEAs with actual values changed cost-effectiveness conclusions in 47% of cases.